$394.5 B

JNJ Mkt cap, 12-Dec-2018
Johnson & Johnson Net income (Q3, 2018)3.9 B
Johnson & Johnson Cash, 30-Sep-201816.1 B
Johnson & Johnson EV407.9 B

Johnson & Johnson Revenue

Johnson & Johnson revenue was $76.45 b in FY, 2017 which is a 6.3% year over year increase from the previous period.

Embed Graph

Johnson & Johnson Revenue Breakdown

Embed Graph

Johnson & Johnson revenue breakdown by business segment: 34.8% from Medical Devices, 47.4% from Pharmaceutical and 17.8% from Consumer

Johnson & Johnson Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

71.3b74.3b70.1b71.9b76.5b

Revenue growth, %

4%(6%)3%6%

Cost of goods sold

22.3b22.7b21.5b21.7b25.4b

Gross profit

49.0b51.6b48.5b50.2b51.1b

Gross profit Margin, %

69%69%69%70%67%

Sales and marketing expense

21.8b22.0b21.2b19.9b21.4b

R&D expense

8.2b8.5b9.0b9.1b10.6b

Operating expense total

30.0b30.4b30.2b29.0b32.0b

Depreciation and amortization

4.1b3.9b3.7b3.8b

EBIT

16.4b21.6b19.2b16.5b

EBIT margin, %

23%29%27%23%

Interest expense

580.0m533.0m552.0m726.0m934.0m

Interest income

74.0m67.0m128.0m368.0m385.0m

Pre tax profit

15.5b20.6b19.2b19.8b17.7b

Income tax expense

1.6b4.2b3.8b3.3b16.4b

Net Income

13.8b16.3b15.4b16.5b1.3b

Johnson & Johnson Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

20.9b14.5b13.7b19.0b17.8b

Accounts Receivable

11.7b11.0b10.7b11.7b13.5b

Prepaid Expenses

4.0b3.5b3.0b3.3b2.5b

Inventories

7.9b8.2b8.1b8.1b8.8b

Current Assets

56.4b59.3b60.2b65.0b43.1b

PP&E

16.7b16.1b15.9b15.9b17.0b

Goodwill

22.8b21.8b21.6b22.8b31.9b

Total Assets

132.7b131.1b133.4b141.2b157.3b

Accounts Payable

6.3b7.6b6.7b6.9b7.3b

Short-term debt

4.9b3.6b7.0b4.7b3.9b

Current Liabilities

25.7b25.1b27.7b26.3b30.5b

Long-term debt

13.3b15.1b12.9b22.4b30.7b

Total Debt

18.2b18.8b19.9b27.1b34.6b

Total Liabilities

58.6b61.4b62.3b70.8b97.1b

Common Stock

3.1b3.1b3.1b3.1b3.1b

Retained Earnings

89.5b97.2b103.9b110.6b101.8b

Total Equity

74.1b69.8b71.2b70.4b60.2b

Debt to Equity Ratio

0.2 x0.3 x0.3 x0.4 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.2 x

Financial Leverage

1.8 x1.9 x1.9 x2 x2.6 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2018

Cash

12.0b10.6b13.6b13.9b18.6b18.2b20.9b12.6b15.7b14.6b17.6b16.1b

Accounts Receivable

11.5b12.0b11.4b11.4b12.1b11.8b12.3b13.3b13.2b14.2b14.1b

Prepaid Expenses

3.7b3.1b3.0b3.3b3.1b2.6b2.8b3.0b2.9b2.6b2.6b

Inventories

8.1b8.3b8.2b8.2b8.5b8.5b8.9b9.7b9.5b9.0b8.8b8.7b

Current Assets

58.2b61.0b63.5b62.7b66.3b63.3b63.3b38.8b41.8b42.8b45.4b47.2b

PP&E

15.4b15.6b15.6b16.0b16.0b16.1b16.2b16.5b40.9b17.0b16.6b16.6b

Goodwill

21.3b21.5b21.3b21.8b22.1b23.2b24.8b31.2b31.3b31.1b30.3b30.7b

Total Assets

129.0b132.0b133.0b136.0b140.0b140.0b145.0b153.0b155.7b156.6b155.4b155.7b

Accounts Payable

6.7b6.1b5.9b6.0b6.1b6.0b6.1b6.1b6.4b6.4b6.5b7.0b

Short-term debt

4.0b5.2b5.7b3.1b1.7b3.4b5.4b7.2b8.5b2.7b2.7b

Current Liabilities

23.8b24.5b25.3b22.1b21.5b23.2b25.1b28.9b31.8b27.1b27.5b27.4b

Long-term debt

14.9b14.1b14.1b20.2b24.5b23.5b27.0b27.4b26.7b29.8b29.4b29.5b

Total Debt

19.0b19.3b19.8b23.3b26.2b27.0b32.4b34.6b35.2b32.5b32.1b29.5b

Total Liabilities

60.7b60.9b61.7b63.6b67.3b67.6b74.6b80.9b81.7b93.4b92.5b91.1b

Common Stock

3.1b3.1b3.1b3.1b3.1b3.1b3.1b3.1b3.1b3.1b3.1b

Retained Earnings

98.7b101.0b103.0b105.0b107.0b109.0b112.0b113.0b114.8b104.3b106.1b107.6b

Total Equity

67.9b71.1b71.6b72.6b72.5b72.8b70.3b71.9b74.0b63.3b62.9b64.6b

Debt to Equity Ratio

0.3 x0.3 x0.3 x0.3 x0.4 x0.4 x0.5 x0.5 x0.5 x0.5 x0.5 x0.5 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x0.2 x

Financial Leverage

1.9 x1.9 x1.9 x1.9 x1.9 x1.9 x2.1 x2.1 x2.1 x2.5 x2.5 x2.4 x

Johnson & Johnson Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

13.8b16.3b15.4b16.5b1.3b

Depreciation and Amortization

4.1b3.9b3.7b3.8b5.6b

Accounts Receivable

(632.0m)(247.0m)(433.0m)(1.1b)(633.0m)

Inventories

(622.0m)(1.1b)(449.0m)(249.0m)581.0m

Accounts Payable

1.8b955.0m(3.0m)656.0m2.7b

Cash From Operating Activities

17.4b18.5b19.3b18.8b21.1m

Purchases of PP&E

(3.6b)(3.7b)(3.5b)(3.2b)(3.3b)

Cash From Investing Activities

(5.1b)(12.3b)(7.7b)(4.8b)(14.9b)

Short-term Borrowings

(1.4b)(1.3b)(1.0b)(2.0b)(1.3b)

Long-term Borrowings

(1.6b)(1.8b)(68.0m)(2.2b)(1.8b)

Cash From Financing Activities

(6.1b)(12.3b)(10.8b)(8.6b)(7.7b)

Net Change in Cash

6.0b(6.4b)(791.0m)5.2b(1.1b)

Interest Paid

596.0m603.0m515.0m730.0m

Income Taxes Paid

3.2b3.5b2.9b2.8b

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2018

Net Income

4.3b8.8b12.2b4.3b8.5b12.7b4.4b8.2b12.0b4.4b8.3b12.3b

Depreciation and Amortization

895.0m1.8b2.7b891.0m1.8b2.7b912.0m2.1b3.8b1.7b3.5b5.2b

Accounts Receivable

(765.0m)(1.2b)(910.0m)(389.0m)(1.1b)(736.0m)(96.0m)(476.0m)(300.0m)(479.0m)(989.0m)(1.0b)

Inventories

(276.0m)(537.0m)(719.0m)(190.0m)(443.0m)(408.0m)(368.0m)(421.0m)(193.0m)(322.0m)(491.0m)(777.0m)

Accounts Payable

(2.5b)(2.2b)1.6b(2.3b)(1.0b)(1.2b)(2.0b)(1.2b)339.0m(1.7b)(49.0m)731.0m

Cash From Operating Activities

2.9b8.1b14.2b1.8b6.8b12.1b2.9b8.7b15.0b3.6b9.7b16.0b

Purchases of PP&E

(543.0m)(1.3b)(2.1b)(639.0m)(1.4b)(2.1b)(560.0m)(1.2b)(2.0b)(658.0m)(1.5b)(2.4b)

Cash From Investing Activities

(1.8b)(5.3b)(6.3b)(1.5b)(215.0m)(2.6b)(936.0m)(13.2b)(14.4b)(925.0m)(1.1b)(5.4b)

Short-term Borrowings

(193.0m)(345.0m)(930.0m)(4.2b)(4.7b)(3.9b)(195.0m)(180.0m)(936.0m)(2.5b)(243.3m)

Long-term Borrowings

(16.0m)(21.0m)(27.0m)(14.0m)(936.0m)(953.0m)(2.0m)(15.0m)(1.0b)(2.0m)(9.0m)

Cash From Financing Activities

(3.2b)(5.7b)(7.6b)(178.0m)(1.6b)(5.1b)(150.0m)(2.1b)(4.1b)(6.0b)(8.6b)(12.1b)

Net Change in Cash

(2.5b)(3.9b)(884.0m)129.0m4.9b4.5b1.9b(6.4b)(3.3b)(3.2b)(255.0m)

Johnson & Johnson Ratios

USDY, 2018

EV/CFO

25.6 x

Debt/Equity

0.5 x

Debt/Assets

0.2 x

Financial Leverage

2.4 x
Report incorrect company information

Johnson & Johnson Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017

Manufacturing Facilities

134 121 119 125

Facilities

265 250 230 260

Countries

60 60 60 60

Discovery Projects

100 150

Drugs Approved by FDA

2
Report incorrect company information

Johnson & Johnson Employee Rating

4.04598 votes
Culture & Values
4.1
Work/Life Balance
3.8
Senior Management
3.5
Salary & Benefits
4.0
Career Opportunities
3.7
Source